Open Label Study of Isotretinoin in Mild to Moderate Alzheimer's Disease

Summary

This is an open label study of isotretinoin, a medication which is FDA approved for treatment of other conditions to determine initial safety in Alzheimer's disease.

Timeline

Start

2012-04

Primary completion

2014-08

Completion

2014-08

Publications

• Background Lee HP, Casadesus G, Zhu X, Lee HG, Perry G, Smith MA, Gustaw-Rothenberg K, Lerner A. All-trans retinoic acid as a novel therapeutic strategy for Alzheimer's disease. Expert Rev Neurother. 2009 Nov;9(11):1615-21. doi: 10.1586/ern.09.86.

Drugs

Indications